
|Videos|November 9, 2021
A Deep Dive on Tapinarof
Author(s)Mary Scoviak, Managing Editor
In this video interview, Mark Lebwohl, MD, explains why topicals for inflammatory conditions are vital for treatment.
Advertisement
Mark G. Lebwohl, MD, professor of dermatology at Mount Sinai, New York, New York, details how tapinarof cream (GSK2894512; Dermavant), a once-daily topical aryl hydrocarbon receptor (AhR) agonist, is effective for psoriasis, gives his thoughts on the current treatment pipeline, and more in this video interview.
Newsletter
Like what you’re reading? Subscribe to Dermatology Times for weekly updates on therapies, innovations, and real-world practice tips.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Dermatology Times
1
Transformative Advances This Year and Beyond
2
FDA Proposes Expansion of US Sunscreen Ingredient Standards with Bemotrizinol
3
Phase 3b Study Confirms Ligelizumab’s Consistent CSU Control
4
The SkinCARE Questionnaire: Assessing the Psychological Dimensions of Skin Health Beyond Disease
5


















